ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Advanced Search Results

  • Title
    ---
  • Authors and Affiliations
    mimi kim
  • 1
  • 2
  • Next Page »
Search Again »
  • Abstract Number: 1672 • ACR Convergence 2024

    The Evaluation of SLE Outcome Measures in Telemedicine

    Maya Souvignier1, Cynthia Aranow2, Anca Askanase1, Mimi Kim3, Diane Kamen4, Cristina Arriens5, Leila Khalili1, Wei Tang6, Maria Dall'Era7 and Meggan Mackay8, 1Columbia University Medical Center, New York, NY, 2Feinstein Institutes for Medical Research, New York, NY, 3Albert Einstein College of Medicine, New York, NY, 4Medical University of South Carolina, Charleston, SC, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Westchester Medical Center, Valhalla, 7UCSF, Corte Madera, CA, 8Feinstein Institutes for Medical Research, Manhasset, NY

    Background/Purpose: Telemedicine (TM) has been integral to rheumatology care since the Covid-19 pandemic; evidence suggests high acceptance, satisfaction, and feasibility. However, due to the complexity…
  • Abstract Number: 1952 • ACR Convergence 2024

    Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry

    Michael Fisher1, Mimi Kim2, Joan Merrill3, Safoah Agyemang1 and Joy Buie1, 1Lupus Foundation of America, Washington, DC, 2Albert Einstein College of Medicine, New York, NY, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: With many treatments under study for SLE, a crisis in recruiting sufficient numbers of qualified patients for clinical trials has emerged. Willingness to consider…
  • Abstract Number: 2400 • ACR Convergence 2024

    Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts

    Melissa Fazzari1, Jane Salmon2, Marta Guerra2, Nathalie Costedoat-Chalumeau3, Veronique LE GUERN4, Gaëlle Guettrot-Imbert4, Marta Mosca5, Dina Zucchi6, Chiara Tani7, Rebecca Fischer-Betz8, Isabell Haase9, Anna Broder10, Navneet Kaur11, Jill Buyon12, Brooke Cohen12, Diane Kamen13, Jessica English14, Anna Arar13 and Mimi Kim15, 1Albert Einstein College of Medicine, Bronx, NY, 2Hospital for Special Surgery, New York, NY, 3Inserm DR Paris 5, Paris, France, 4Cochin hospital, Paris, France, 5University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 6Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 7University of Pisa, Pisa, Italy, 8Uniklinik Düsseldorf, Düsseldorf, Germany, 9Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, 10Hackensack Network, Hackensack, NJ, 11Touro University Medical Group, Sacramento, CA, 12NYU Grossman School of Medicine, New York, NY, 13Medical University of South Carolina, Charleston, SC, 14Medical University of South Carolina, Johns Island, SC, 15Albert Einstein College of Medicine, Larchmont, NY

    Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…
  • Abstract Number: 2055 • ACR Convergence 2022

    SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?

    Alfredo Aguirre1, Mimi Kim2, Kosalaram Goteti3, Ying Li3, Amy Kao4, Nathalie Franchimont5, George Kong5, Catherine Barbey6, Qing Zuraw7, Robert Gordon7, David Manner8, Maria Silk9, Teodora Staeva10, Hoang Nguyen11, Richard Furie12, Matthew Linnik13 and Maria Dall'Era14, 1University of California, San Francisco, San Francisco, CA, 2Albert Einstein College of Medicine, Larchmont, NY, 3EMD Serono, Boston, MA, 4EMD Serono, Billerica, MA, 5Biogen, Cambridge, MA, 6Biogen, Baar, Switzerland, 7Janssen Research and Development, LLC, Spring House, PA, 8Eli Lilly and Company, Indianapolis, IN, 9Eli Lilly, Carmel, IN, 10Lupus Research Alliance, New York, NY, 11Lupus Research Alliance, Houston, TX, 12Northwell Health, Great Neck, NY, 13Eli Lilly and Company, San Diego, CA, 14University of California, Division of Rheumatology, San Francisco, CA

    Background/Purpose: The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) are currently the most…
  • Abstract Number: 1268 • ACR Convergence 2021

    Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods

    Melissa Fazzari1, Marta Guerra2, Jane Salmon2 and Mimi Kim3, 1Albert Einstein College of Medicine, Bronx, NY, 2Hospital for Special Surgery, New York, NY, 3Albert Einstein College of Medicine, Larchmont, NY

    Background/Purpose: Nearly 20% of pregnancies in patients with Systemic lupus erythematosus (SLE) result in an adverse pregnancy outcome (APO); early identification of women with SLE…
  • Abstract Number: 1299 • ACR Convergence 2021

    Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network

    Peter Izmirly1, Maria Dall'Era2, Kenneth Kalunian3, Kristina Deonaraine1, Mimi Kim4, Philip Carlucci1, Jessica Li5, Andrea Fava5, H. Michael Belmont6, Chaim Putterman7, Jennifer Anolik8, Betty Diamond9, David Wofsy10, Diane Kamen11, Judith James12, Accelerating Medicines Partership (AMP) RA/SLE Network13, Deepak Rao14, The Accelerating Medicines Partnership in SLE Network15, Michelle Petri16, Jill Buyon6 and Richard Furie17, 1New York University School of Medicine, New York, NY, 2University of California San Francisco, Corte Madera, CA, 3UC San Diego, La Jolla, CA, 4Albert Einstein College of Medicine, Larchmont, NY, 5Johns Hopkins University, Baltimore, MD, 6NYU School of Medicine, New York, NY, 7Albert Einstein College of Medicine, Bronx, NY, 8University of Rochester Medical Center, Rochester, NY, 9Northwell Health, Manhasset, NY, 10University of California San Francisco, San Francisco, CA, 11Medical University of South Carolina, Charleston, SC, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Brigham and Women's Hospital, Everett, MA, 14Brigham and Women's Hospital, Boston, MA, 15Multiple Institutions, Multiple Cities, 16Johns Hopkins University School of Medicine, Baltimore, MD, 17Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY

    Background/Purpose: The Accelerating Medicines Partnership (AMP) Lupus Network was established with the goal of applying novel technologies to the interrogation of blood and tissue samples…
  • Abstract Number: 1420 • ACR Convergence 2021

    Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus

    Peter Izmirly1, Mimi Kim2, Marie Samanovic-Golden3, Ruth Fernandez Ruiz4, Sharon Ohana3, Alexis Engel5, Kristina Deonaraine1, Mala Masson4, Xianhong Xie6, Amber Cornelius4, Ramin Herati4, Rebecca Haberman4, Jose Scher1, Allison Guttmann3, Rebecca Blank7, Ben Plotz3, Mayce Haj-Ali4, Brittany Banbury3, Sara Stream8, Ghadeer Hasan3, Gary Ho3, Paula Rackoff7, Ashira Blazer3, H. Michael Belmont3, Amit Saxena3, Mark Mulligan4, Robert Clancy4 and Jill Buyon3, 1New York University School of Medicine, New York, NY, 2Albert Einstein College of Medicine, Larchmont, NY, 3NYU School of Medicine, New York, NY, 4NYU Grossman School of Medicine, New York, NY, 5NYU Langone Health, New Yok, NY, 6Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, 7New York University, New York, NY, 8NYU Langone Health, New York, NY

    Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data…
  • Abstract Number: 1500 • ACR Convergence 2020

    Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation

    Deborah Friedman1, Mimi Kim2, Nathalie Costedoat-Chalumeau3, Robert Clancy4, Joshua Copel5, Colin Phoon6, Bettina Cuneo7, Rebecca Cohen6, Mala Masson6, Benjamin Wainwright6, Noel Zahr8, Amit Saxena4, Peter Izmirly9 and Jill Buyon10, 1New York Medical College, Valhalla, 2Albert Einstein College of Medicine, Bronx, 3APHP, Université de Paris, Paris, France, 4NYU School of Medicine, New York, 5Yale School of Medicine, New Haven, 6New York University School of Medicine, New York, 7University of Colorado School of Medicine, Aurora, 8Pitié-Salpêtrière University Hospital, Paris, France, 9Department of Medicine, New York University School of Medicine, New York, NY, 10Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine (HCQ) was initially considered as a prophylaxis and treatment of COVID-19. …
  • Abstract Number: 1274 • ACR Convergence 2020

    COVID-19 in Patients with Systemic Lupus Erythematosus

    Ruth Fernandez-Ruiz1, Mala Masson1, Mimi Kim2, Benjamin Myers3, Rebecca Haberman4, Jose Scher4, Rochelle Castillo4, Allison Guttmann1, Philip Carlucci1, Kristina Deonaraine1, Michael Golpanian5, Kimberly Robins1, Miao Chang1, H. Michael Belmont6, Jill Buyon7, Ashira Blazer6, Amit Saxena8 and Peter Izmirly9, 1New York University School of Medicine, New York, 2Albert Einstein College of Medicine, Bronx, 3Cornell University, Ithica, NY, 4NYU School of Medicine, New York City, 5New York University, New York, NY, 6NYU School of Medicine, New York, NY, 7Department of Medicine, NYU School of Medicine, New York, NY, 8NYU School of Medicine, New York, 9Department of Medicine, New York University School of Medicine, New York, NY

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for coronavirus disease 2019 (COVID-19) with biologic, genetic, demographic, clinical and…
  • Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting

    The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block

    Peter Izmirly1, Mimi Kim 2, Nathalie Costedoat-Chalumeau 3, Deborah Friedman 4, Amit Saxena 5, Joshua Copel 6, Rebecca Cohen 1, Mala Masson 1, Tishaun Middleton 1, Kimberly Robins 1, Robert Clancy 1 and Jill Buyon 1, 1NYU School of Medicine, New York, 2Albert Einstein College of Medicine, Bronx, NY, 3Cochin University Hospital, Paris, France, 4New York Medical College, Valhalla, 5New York University School of Medicine, New York, NY, 6Yale School of Medicine, New Haven

    Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…
  • Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting

    Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data

    Mimi Kim1, Kith Pradhan 1, Peter Izmirly 2, Kenneth Kalunian 3, Leslie Hanrahan 4 and Joan Merrill 5, 1Albert Einstein College of Medicine, Bronx, NY, 2New York University School of Medicine, New York, 3University of California at San Diego, San Diego, 4Lupus Foundation of America, Washington DC, 5Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…
  • Abstract Number: 2866 • 2019 ACR/ARP Annual Meeting

    Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus

    Amit Saxena1, Peter Izmirly 2, Rebecca Bomar 3, Shireen Golpanian 4, Deborah Friedman 5, Ruth Eisenberg 6, Mimi Kim 7 and Jill Buyon 2, 1New York University School of Medicine, New York, NY, 2NYU School of Medicine, New York, 3New York University School of Medicine, New York, NY, New York, 4Miami Miller School of Medicine, Miami, 5New York Medical College, Valhalla, 6Albert Einstein College of Medicine, New York, 7Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Cardiac manifestations of neonatal lupus (NL) have been associated with significant morbidity and mortality, however there has been minimal information on long-term outcomes of…
  • Abstract Number: 1854 • 2018 ACR/ARHP Annual Meeting

    SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates

    Julia Davis-Porada1, Sam Stern2, Marta M. Guerra3, Carl Laskin4,5, Michelle Petri6, Michael Lockshin7, Lisa R Sammaritano8,9, David Branch10,11, Allen D. Sawitzke12, Joan T. Merrill13,14, Jill P. Buyon15, Mimi Kim16 and Jane E. Salmon8,9, 1Research, Hospital for Special Surgery, New York, NY, 2Albert Einstein College of Medicine, New York, NY, 3Department of Medicine and Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, 4Mount Sinai Hospital Toronto, Toronto, ON, Canada, 5Trio Fertility, Toronto, ON, Canada, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7Barbara Volcker Center, Hospital for Special Surgery, New York, NY, 8Hospital for Special Surgery, New York, NY, 9Weill Cornell Medicine, New York, NY, 10Intermountain Healthcare, Salt Lake City, UT, 11Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, 12Rheumatology, University of Utah Health Sciences Center, Salt Lake City, UT, 13University of Oklahoma Health Sciences Center, Oklahoma City, OK, 14Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Medicine, New York University School of Medicine, New York, NY, 16Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects women of childbearing age. Low disease activity for 6 months prior to conception leads to the best outcomes;…
  • Abstract Number: 2931 • 2018 ACR/ARHP Annual Meeting

    Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects

    Mimi Kim1, Joan T. Merrill2, Kenneth C. Kalunian3, Leslie Hanrahan4 and Peter M. Izmirly5, 1Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 4Lupus Foundation of America, Washington DC, DC, 5NYU Langone Health, New York, NY

    Background/Purpose:  Missing data due to drop-out and loss to follow-up is a common problem in SLE trials. The usual approaches for handling this issue include…
  • Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting

    Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials

    Mimi Kim1, Joan T. Merrill2, Kenneth C. Kalunian3, Leslie Hanrahan4 and Peter M. Izmirly5, 1Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 4Lupus Foundation of America, Washington DC, DC, 5Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
  • 1
  • 2
  • Next Page »
Search Again »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology